Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium

Molecular Therapy

Volumn 10, Issue 4, 2004, Pages 697-705

  Ramesh, Nagarajan ^a   Memarzadeh, Bahram ^a   Ge, Ying ^a   Frey, David ^a   VanRoey, Melinda ^a   Rojas, Virginia ^a   Yu, De Chao ^a  

^a CELL GENESYS INC   (United States)

Author keywords

Adenovirus; Bladder; Glycosaminoglycan; Pretreatment; Tight junction

Indexed keywords

ADENOVIRUS VECTOR; CARBOHYDRATE DERIVATIVE; CHLORPACTIN WCS 90; DISACCHARIDE; DODECYL SULFATE SODIUM; GLYCOSAMINOGLYCAN; N DODECYL DEXTRO MALTOSIDE; ONCOLYTIC VIRUS; OXYCHLOROSENE; POLIDOCANOL; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CANCER THERAPY; CONTROLLED STUDY; FEMALE; GENE TRANSFER; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PERMEABILITY BARRIER; RAT; TARGET CELL; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BENZENESULFONATES; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLUCOSIDES; GLYCOSAMINOGLYCANS; MICE; RATS; SODIUM DODECYL SULFATE; URINARY BLADDER; UROTHELIUM;

ADENOVIRIDAE; MURINAE;

EID: 4644259118     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.07.002     Document Type: Article

References (32)

1. R.T. Greenlee T. Murray S. Bolden P.A. Wingo Cancer statistics CA J. Cancer Clin. 50 2000 7-33
2. W. Hassen M.J. Droller Current concepts in assessment and treatment of bladder cancer Curr. Opin. Urol. 10 2000 291-299
3. H.W. Herr Tumor progression and survival of patients with grade, noninvasive papillary (TaG3) tumors: 15-year outcome J. Urol. 163 2000 60-61
4. B.D. Morris et al. Adenoviral-mediated gene transfer to bladder in vivo J. Urol. 152 1994 506-509
5. C. Bass et al. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo Cancer Gene Ther. 2 1995 97-104
6. D.H. Palmer V. Mautner D.J. Kerr Clinical experience with adenovirus in cancer therapy Curr. Opin. Mol. Ther. 4 2002 423-434
7. G.J. Bauerschmitz S.D. Barker A. Hemminki Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents Int. J. Oncol. 21 2002 1161-1174
8. A. Amalfitano R.J. Parks Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy Curr. Gene Ther. 2 2002 111-133
9. Q. Wu T. Moyana J. Xiang Cancer gene therapy by adenovirus-mediated gene transfer Curr. Gene Ther. 1 2001 101-122
10. D.-C. Yu P. Working D. Ando Selectively replicating oncolytic adenoviruses as cancer therapeutics Curr. Opin. Mol. Ther. 4 2002 435-443
11. S.F. Stanziale Y. Fong Novel approaches to cancer therapy using oncolytic viruses Curr. Mol. Med. 3 2003 61-71
12. C. Biederer S. Ries C.H. Brandts F. McCormick Replication-selective viruses for cancer therapy J. Mol. Med. 80 2002 163-175
13. J. Zhang et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel Cancer Res. 62 2002 3743-3750
14. J.P. Lavelle G. Apodaca S.A. Meyers W.G. Ruiz M.L. Zeidel Disruption of guinea pig urinary bladder permeability barrier in noninfectious cystitis Am. J. Physiol. Renal Physiol. 274 1998 F205-F214
15. S.A. Lewis J.R. Berg T.J. Kleine Modulation of epithelial permeability by extracellular macromolecules Physiol. Rev. 75 1995 561-589
16. H.O. Negrete J.P. Lavelle J. Berg S.A. Lewis M.L. Zeidel Permeability properties of the intact mammalian bladder epithelium Am. J. Physiol. Renal Physiol. 271 1996 F886-F894
17. P. Hu et al. Role of membrane proteins in permeability barrier function: uroplakin ablation elevates urothelial permeability Am. J. Physiol. Renal Physiol. 283 2002 F1200-F1207
18. J.D. Lilly C.L. Parson Bladder surface glycosaminoglycans is a human epithelial permeability barrier Surg. Gynecol. Obstet. 171 1990 493-496
19. H. Engler et al. Ethanol improves adenovirus mediated gene transfer and expression to the bladder epithelium of rodents Urology 53 1999 1049-1053
20. L.-F. Lin et al. A system for the enhancement of adenovirus mediated gene transfer to uroepithelium J. Urol. 168 2002 813-818
21. M. Yamashita et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer Cancer Gene Ther. 9 2002 687-691
22. R.J. Conner et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium Gene Ther. 8 2001 41-48
23. R.D. Siemens C.J. Austin W.A. See J. Tartaglia T.L. Ratliff Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium J. Urol. 165 2001 667-671
24. D.C. Yu Y. Chen M. Seng J. Dilley D.R. Henderson The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res. 59 1999 4200-4203
25. C.L. Parsons C. Greenspan S.G. Mulholland The primary antibacterial defense mechanisms of the bladder Invest. Urol. 13 1975 72-76
26. C.L. Parsons D. Boychuk S. Jones R. Hurst H. Callahan Bladder surface glycosaminoglycans: an epithelial permeability barrier J. Urol. 143 1990 139-142
27. S.D. Niku P.C. Stein H.C. Scherz C.L. Parson A new method for cytodestruction of bladder epithelium using protamine sulfate and urea J. Urol. 152 1994 1025-1028
28. J.M. Bergelson et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 Science 275 1997 1320-1323
29. T. Honda et al. The coxsackievirus - adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain Brain Res. Mol. Brain Res. 77 2000 19-28
30. C.J. Cohen hieh R.J. Pickles T. Okegawa J.T. Hsieh J.M. Bergelson The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction Proc. Natl. Acad. Sci. USA 98 2001 15191-15196
31. R.W. Walters P. Freimuth T.O. Moninger I. Ganske J. Zabner M.J. Welshm Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape Cell 110 2002 789-799
32. E.G. Spack N.G. Wehner J.L. Winkelhake Preclinical and pharmacological studies of AG284, a soluble HLA-DR2: myelin basic protein peptide complex for the treatment of multiple sclerosis CNS Drug Rev. 4 1998 225-246